Orion Oyj stock | Price target for 2026, price & analyst rating

Orion Oyj

HLSE:ORNBV

€ 71,70

+ €0,10 (0,14%)

71,70 €

+€0,10 (0,14%)

End-of-day quote: 04/02/2026

Orion Oyj Stock Value

The analyst rating for Orion Oyj is currently Outperform.

Outperform

Orion Oyj Company Info

EPS Growth 5Y

17,94%

Market Cap

€10,08 B

Long-Term Debt

€0,12 B

Quarterly earnings

04/23/2026

Dividend

€1,80

Dividend Yield

2,51%

Founded

1917

Industry

Health Care

Country

Finland

Website

Orion Oyj

ISIN Number

FI0009014377

Website

http://www.orion.fi

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€75,00

4.6%

Last Update: 04/03/2026

Analysts: 6

Highest Price Target €79,00

Average Price Target €75,00

Lowest Price Target €55,00

In the last five quarters, Orion Oyj’s Price Target has risen from €33,88 to €52,20 - a 54,07% increase. Six analysts predict that Orion Oyj’s share price will increase in the coming year, reaching €75,00. This would represent an increase of 4,60%.

Top growth stocks in the health care sector (5Y.)

What does Orion Oyj do?

Orion Oyj is a Finnish pharmaceutical company committed to developing and providing innovative products in the healthcare sector, primarily focusing on pharmaceuticals and active pharmaceutical ingredients (APIs). The company operates globally and emphasizes regulatory compliance, sustainability, and customer-centric strategies to navigate the complexities of the pharmaceutical industry. Through its advanced research and development capabilities, the company strives to maintain a competitive e...

The company operates globally and emphasizes regulatory compliance, sustainability, and customer-centric strategies to navigate the complexities of the pharmaceutical industry. Through its advanced research and development capabilities, the company strives to maintain a competitive edge while adhering to the highest standards of quality and safety in its products.

Business Segments

The company operates through manufacture of active pharmaceutical ingredients (APIs), the manufacturing of medicinal products, and a range of specialized services for customers in the pharmaceutical industry segments.

The API segment focuses on the production of advanced active ingredients essential for various therapeutic applications. This includes a wide array of products tailored to customer specifications and regulatory requirements. The company's subsidiary, Fermion, plays a pivotal role in this segment by supplying APIs to the company and other pharmaceutical companies, further fortifying the company's standing in the industry.

In the medicinal products segment, the company is heavily involved in the manufacture of therapeutic medications that serve various medical disciplines. The product lineup includes a range of approved medicinal products as well as ongoing projects aimed at developing innovative treatment options. The company recognizes the importance of adhering to scientific regulations and industry practices, thereby ensuring the efficacy and safety of its pharmaceutical offerings.

Additionally, the company's operational model incorporates strategic collaboration with other enterprises for clinical development and commercialization. This collaboration reinforces the company's position as a significant player in the global pharmaceutical landscape, enabling it to innovate while managing risks effectively.

Business Strategy

The company adopts a strategy that harnesses its core competencies in research, development, and manufacturing to address market needs. The company emphasizes the importance of innovation and sustainability in every aspect of its operations. This entails committing significant resources towards research and development to create new therapeutic solutions and improve existing products. In terms of market strategy, the company targets both local and international markets, adapting its offerings to comply with local regulatory standards and customer preferences.

A crucial component of the company's strategy is the ongoing development of partnerships with other pharmaceutical companies, which allows for shared knowledge and resources. This cooperative approach is especially evident in clinical developments, where the company collaborates to expedite the commercialization of new drugs while distributing risk. The adaptability in the company's business model also reflects a commitment to addressing the evolving landscape of healthcare needs.

Products and Services

The company's product portfolio is extensive, offering a wide range of pharmaceutical solutions. The company's primary products include both active pharmaceutical ingredients (APIs) and finished medicinal products. The APIs are manufactured at Fermion and cater to various therapeutic uses, serving both the company's internal needs and those of external partners.

In terms of medicinal products, the company focuses on several therapeutic areas, including central nervous system disorders, oncology, cardiovascular health, and other chronic diseases. The company continually invests in research to create new treatments that address unmet medical needs.

Services provided by the company extend beyond product offerings, including consulting for regulatory compliance and support during drug development phases. The company provides end-to-end solutions that assist clients in navigating complex regulatory processes and bringing products to market more efficiently.

Geographical Markets Served

The company serves a diverse geographical market, with a presence in numerous countries around the world. The company's global outreach enables it to leverage various market opportunities and cater to the needs of diverse clients effectively. The company maintains operations not just in Finland but also across Europe and other international markets. This broad market coverage enhances its ability to adapt to varying customer preferences, regulatory frameworks, and market dynamics.

Seasonality

The company's business is somewhat influenced by seasonal factors, particularly in relation to product demand and regulatory cycles. Certain therapeutic products may see fluctuations in demand based on seasonal conditions or specific therapeutic needs that arise during particular periods. However, the overall impact of seasonality on the company's operations tends to be mitigated by its diversified product portfolio and geographical market presence.

Customers

The company serves a diverse array of customers within the pharmaceutical sector. The company's clientele includes healthcare providers, other pharmaceutical companies, and various institutions in need of medicinal products and active pharmaceutical ingredients. While specific names of customers may vary, the company's business model emphasizes a collaborative approach to meet the specific needs of its B2B partners. The number of customers served by the company is substantial, encompassing tens of thousands of entities globally, reflecting the company's critical role in the pharmaceutical supply chain.

Sales and Marketing

The company employs a multifaceted marketing strategy to reach its diverse customer base. Its sales approach encompasses direct sales teams, partnerships with distributors, and participation in pharmaceutical trade shows and conferences to connect with potential clients. Additionally, the company adopts digital marketing techniques and data-driven strategies to better understand market dynamics and improve customer engagement. By utilizing a combination of traditional and modern marketing approaches, the company effectively addresses the unique needs of customers across different geographical markets.

History

Orion Oyj was founded in 1917.

Orion Oyj Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 85% **Diagnostic Sales:** 10% **Other Sales:** 5% **TOP 3 Markets:** 1. **Finland:** 35% 2. **Germany:** 20% 3. **Sweden:** 15% Orion Oyj generates the majority of its sales from the pharmaceutical industry, accounting for approximately 85% of total revenue....

At which locations are the company’s products manufactured?

**Production sites of Orion Oyj:** 1. **Espoo, Finland** 2. **Turku, Finland** 3. **Salo, Finland** 4. **Kuopio, Finland** Orion Oyj is a leading company in the pharmaceutical industry in Finland. The main production facilities are located in Espoo, Turku, Salo, and Kuopio. These sites are strateg...

What strategy does Orion Oyj pursue for future growth?

**Focus on Research and Development:** 15% of revenue (2024) **Expansion into New Markets:** Asia and North America **Partnerships and Acquisitions:** Targeted acquisitions in the field of oncology Orion Oyj pursues a growth strategy that heavily emphasizes research and development. In 2024, the...

Which raw materials are imported and from which countries?

**Main raw materials:** Active ingredients, excipients, packaging materials **Countries of origin:** Germany, India, China, USA Orion Oyj, a Finnish pharmaceutical company, imports various raw materials and materials necessary for the production of their pharmaceutical products. This includes in p...

How strong is the company’s competitive advantage?

**Market share in the pharmaceutical industry:** 4.5% (2024, estimated) **R&D investments:** 12% of revenue (2024) **Patent portfolio:** Over 150 active patents (2024) Orion Oyj has a significant competitive advantage in the pharmaceutical industry, which is manifested through several factors....

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (estimated for 2025) **Insider Buys/Sells:** No significant transactions in the last quarter (estimated for 2025) The institutional investor share in Orion Oyj is around 45%, indicating a solid trust from institutional investors in the company. Th...

What percentage market share does Orion Oyj have?

**Market share of Orion Oyj:** 4.5% (estimated, 2025) **Top competitors and their market shares:** 1. **Novo Nordisk:** 15.2% 2. **Roche:** 12.8% 3. **Sanofi:** 11.5% 4. **AstraZeneca:** 9.3% 5. **GlaxoSmithKline (GSK):** 8.7% 6. **Pfizer:** 8.0% 7. **Bayer:** 6.5% 8. **Novartis:** 5.9% 9. **Merck...

Is Orion Oyj stock currently a good investment?

**Revenue growth:** 8.2% (2024) **Research and development investments:** 12% of revenue (2024) **Market share in oncology:** 5% (2024) Orion Oyj recorded a revenue growth of 8.2% in 2024, attributed to a strong product pipeline and successful market launches. Particularly noteworthy is the oncolog...

Does Orion Oyj pay a dividend – and how reliable is the payout?

**Dividend Yield:** 3.5% (estimated for 2025) **Dividend History:** Continuous payout over the last 10 years Orion Oyj is known for its stable dividend policy. The company has consistently distributed dividends to its shareholders over the past ten years. The estimated dividend yield for 2025 is...

New support ticket

Explore

Orion Oyj Stock Value

Orion Oyj Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Orion Oyj do?

Orion Oyj Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Orion Oyj Stock Value

Orion Oyj Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Orion Oyj do?

Orion Oyj Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.